What is Competitive Landscape of Myriad Company?

Myriad Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the Competitive Landscape of Myriad Genetics?

The molecular diagnostics industry is rapidly evolving, with technological advancements and changing healthcare needs shaping its future. Myriad Genetics, a key player in this sector, is actively navigating this dynamic environment. The company, which reported full-year 2024 revenue of $838 million, a 11% increase year-over-year, continues to adapt its strategies to maintain its competitive edge.

Myriad Genetics, founded in 1991, pioneered hereditary cancer risk testing, notably with its BRACAnalysis test. This early innovation allowed the company to establish and dominate the market for hereditary cancer genetic testing. Today, Myriad continues to evolve, focusing on its Cancer Care Continuum to adapt its business model in a sector that demands constant innovation and strategic realignment.

What is the competitive landscape of Myriad Genetics?

Myriad Genetics reported Q2 2025 revenue of $213.1 million, a 1% year-over-year increase. The company has also updated its full-year 2025 revenue guidance to a range of $818 million to $828 million. This ongoing financial performance underscores Myriad's continued presence and strategic focus. Understanding its market position, key rivals, and core advantages is crucial for assessing its future prospects. A deeper dive into its market dynamics can be found in the Myriad PESTEL Analysis.

Myriad Genetics is a significant player in molecular diagnostics, focusing on oncology, women's health, and mental health pharmacogenomics. The company's market position is built on its specialized testing services designed to guide treatment decisions and improve patient outcomes.

Core Business Areas

Myriad Genetics leads in molecular diagnostics across oncology, women's health, and mental health pharmacogenomics. Its offerings aim to personalize patient care through advanced testing solutions.

Key Product Lines

The company's portfolio includes hereditary cancer tests like MyRisk with RiskScore, prostate cancer test Prolaris, and tumor profiling tests Precise MRD and Precise Liquid. It also offers prenatal screening (Prequel) and carrier screening (Foresight), alongside the GeneSight Psychotropic test.

Financial Performance Overview

For the full year 2024, Myriad Genetics reported revenue of $838 million, an 11% increase year-over-year. The first quarter of 2025 saw revenue of $196 million, a 3% decrease compared to the previous year, though adjusted for specific headwinds, it represented a 5% increase.

Revenue Growth and Guidance

Second quarter 2025 revenue reached $213.1 million, up 1% year-over-year, with adjusted gross margin at 71.2%. The company projects full-year 2025 revenue between $818 million and $828 million.

Myriad Genetics' strategic focus has shifted towards the Cancer Care Continuum (CCC) as its primary growth driver, aiming to enhance its leadership in hereditary cancer testing and expand into areas like therapy selection and MRD detection. This strategic pivot is crucial for navigating the competitive landscape and capitalizing on emerging opportunities in precision medicine. Understanding Myriad company's competitive advantages in these evolving segments is key to assessing its future market position.

Geographic Reach and Strategic Focus

Operating primarily in the United States, Myriad Genetics also has an international presence. The company's strategic emphasis on the Cancer Care Continuum (CCC) since 2024-2025 highlights its commitment to expanding its leadership in hereditary cancer testing and entering high-growth areas.

• Hereditary cancer testing leadership
• Expansion into therapy selection
• Immuno-oncology response monitoring
• Molecular Residual Disease (MRD) detection

While prenatal testing revenue saw an 11% increase in Q1 2025 and hereditary cancer testing volume grew by 11% in the same period, the pharmacogenomics segment experienced a significant decline. Revenue in this segment dropped 20% in Q1 2025 and 12% in Q2 2025, largely due to a major payer's decision to discontinue coverage for multi-gene panel pharmacogenetic testing, impacting the GeneSight test. This situation underscores the sensitivity of Myriad's market share to payer policies and highlights a key competitive threat. Analyzing Myriad company's competitive threats in this context is vital.

Competitive Benchmarking

Myriad's trailing 12-month revenue of approximately $800 million places it fourth among its top ten competitors, whose average revenue stands at $2 billion. This comparison provides a clear indication of its market share relative to industry leaders.

• Myriad's revenue: ~$800 million (trailing 12 months)
• Top 10 competitors' average revenue: $2 billion
• Myriad ranks fourth among its top ten competitors

The company's financial results in Q2 2025 included a GAAP net loss, primarily due to a substantial $316.7 million non-cash impairment charge. Despite this, the adjusted EPS for the quarter was $0.05. The company's ability to navigate such financial impacts while pursuing its strategic growth initiatives is a critical aspect of its competitive strategy. For a deeper dive into its historical trajectory, refer to the Brief History of Myriad. Understanding Myriad company's competitive strategy is essential for evaluating its long-term prospects. The key players in Myriad company's market are diverse, ranging from large diagnostic companies to specialized genetic testing providers.

Myriad SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The molecular diagnostics market is a dynamic arena where Myriad Genetics faces robust competition. Its primary direct rivals in hereditary cancer testing are Invitae and Ambry Genetics. These companies are recognized for their extensive genetic testing portfolios and often compete by offering more accessible and affordable options.

In the non-invasive prenatal testing (NIPT) sector, a key area within women's health, Myriad contends with players like Natera and Illumina, which utilize advanced sequencing technologies. The pharmacogenomics field, where Myriad's GeneSight test is a significant offering, sees competition from emerging companies and academic institutions developing new tests guided by Next-Generation Sequencing (NGS) advancements.

Hereditary Cancer Testing Rivals

Invitae and Ambry Genetics are key direct competitors in hereditary cancer testing. They often differentiate through broader test menus and competitive pricing strategies.

Women's Health Segment Competition

In non-invasive prenatal testing (NIPT), Natera and Illumina are significant competitors. They leverage advanced sequencing technologies to compete in this growing market.

Pharmacogenomics Market Dynamics

Emerging companies and academic institutions are developing new pharmacogenomic tests. These innovations, driven by NGS, challenge Myriad's GeneSight test.

Broader Industry Competitors

Other notable players across various segments include Labcorp, Quest Diagnostics, Exact Sciences, Guardant Health, NeoGenomics, Qiagen, Roche, and Thermo Fisher Scientific.

Impact of Patent Rulings

The 2013 U.S. Supreme Court ruling invalidating key gene patents, like those for BRCA1/2, significantly increased competition and accessibility in hereditary cancer testing.

Recent Payer Policy Changes

A decision by UnitedHealthcare to discontinue coverage for multi-gene panel pharmacogenetic testing from Q1 2025 impacted Myriad's GeneSight revenue, with a 20% decline in Q1 2025 and 12% in Q2 2025.

Technological Disruption and Future Outlook

The competitive landscape is continuously reshaped by new entrants and technological advancements, particularly in artificial intelligence (AI) and machine learning. AI in clinical and molecular diagnostics is projected for significant growth by 2029, indicating a future where data-driven insights will play an even larger role in shaping market dynamics and competitive strategies.

• Myriad company competitive analysis involves understanding direct and indirect rivals.
• Key players in Myriad company's market include Invitae, Ambry Genetics, Natera, and Illumina.
• Technological advancements, especially AI, are a significant factor in the competitive landscape.
• Payer policy changes, like UnitedHealthcare's decision, can materially affect revenue streams.
• Understanding Myriad company's competitive advantages requires benchmarking against industry leaders.
• The Competitors Landscape of Myriad highlights the evolving market.

Myriad PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Myriad Genetics has established a strong market position through a combination of proprietary technology, a comprehensive product suite, and strategic R&D investments. The company's competitive edge is significantly bolstered by its intellectual property, particularly patents covering hereditary cancer genes and advanced diagnostic methodologies.

The firm's long-standing expertise in genetic testing has cultivated substantial brand recognition and customer loyalty. Despite changes in patent law, its extensive database of genetic test results remains a valuable asset for interpreting complex genetic data, offering a distinct advantage in identifying variants of unknown significance.

Proprietary Technology and IP Portfolio

Myriad's competitive advantage is rooted in its extensive intellectual property, including patents for hereditary cancer genes and diagnostic methods. The company continues to innovate, securing patents for its Molecular Residual Disease (MRD) assay, Precise MRD, which utilizes whole-genome sequencing for ultra-low ctDNA detection.

Brand Equity and Data Interpretation Capabilities

The company's history as a pioneer in genetic testing has built significant brand equity and customer loyalty. Its vast database of genetic test results provides a unique ability to interpret ambiguous findings, such as variants of unknown significance, differentiating it from industry rivals.

Operational Efficiency and Financial Performance

Myriad benefits from operational efficiencies, evidenced by an improved adjusted gross margin of 71.2% in Q2 2025. This focus on efficiency supports its investment in research and development and market expansion.

Continuous Innovation and Product Launches

A strong commitment to R&D drives the consistent introduction of new precision medicine tests. Recent launches include the Prequel Early Gestational Age test in late 2024, with Precise MRD and Precise Liquid tests slated for 2025 commercial launch, enhancing its product portfolio.

Strategic Investments and Future Outlook

Myriad is strategically investing in cutting-edge technologies and expanding its data-sharing initiatives, such as the Myriad Collaborative Research Registry (MCRR), which includes data from over one million patients. The company is also integrating AI, with plans for an AI-driven prostate cancer test in partnership with PATHOMIQ in Q1 2026, underscoring its forward-looking competitive strategy.

• Expansion of Molecular Residual Disease (MRD) testing capabilities.
• Integration of Artificial Intelligence (AI) into diagnostic tools.
• Growth of its data registry for enhanced research and interpretation.
• Focus on the Cancer Care Continuum strategy for sustained leadership.
• Continued development of new precision medicine tests.

Myriad Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The molecular diagnostics industry is in a state of rapid evolution, driven by technological advancements and expanding applications. This dynamic environment presents both significant growth avenues and considerable challenges for companies like Myriad Genetics. Understanding the current industry trends is crucial for assessing Myriad company's market position and its competitive strategy.

Key industry trends include the integration of artificial intelligence (AI) and machine learning, which are improving diagnostic accuracy and predictive capabilities. The AI in Clinical and Molecular Diagnostics Market is projected to grow substantially, reaching $8.9 billion by 2029. Furthermore, precision medicine is broadening its reach beyond oncology into areas such as neurology and autoimmune diseases. The Molecular Residual Disease (MRD) testing market, a key focus for Myriad, is also expected to see robust growth, projected to reach $3.54 billion by 2030. These trends highlight opportunities for Myriad company to leverage new technologies and expand into new therapeutic areas.

AI and Machine Learning Integration

The increasing adoption of AI and machine learning is enhancing diagnostic precision and predictive analytics. This trend offers Myriad company opportunities to integrate AI into its testing platforms, as seen with its planned AI-driven prostate cancer test.

Expansion of Precision Medicine

Precision medicine is expanding beyond oncology into new therapeutic areas like neurology and autoimmune diseases. This broader market growth indicates a positive outlook for companies focused on personalized diagnostics.

Molecular Residual Disease (MRD) Market Growth

The MRD testing market is a significant growth area, with projections indicating substantial expansion. Myriad's focus on its Precise MRD test positions it to capitalize on this increasing demand within the molecular diagnostics sector.

Macroeconomic and Regulatory Challenges

The industry faces headwinds from macroeconomic factors and evolving regulatory landscapes. Data privacy and security are paramount concerns, especially with the increasing use of sensitive genetic information.

Myriad's Strategic Response to Challenges and Opportunities

Despite industry challenges, Myriad is implementing a strategic overhaul focused on the Cancer Care Continuum to drive growth. This includes strengthening its hereditary cancer testing leadership and expanding into high-growth segments like therapy selection and MRD detection. The company is also focused on enhancing organizational capabilities and operational efficiencies to achieve its revenue growth targets.

• Commercial launch of Precise MRD and Precise Liquid tests planned for 2025.
• FirstGene Multiple Prenatal Screen set for launch in 2026.
• Focus on improving execution and organizational capabilities.
• Aiming for high single-digit to low double-digit revenue growth over the next five years.
• Understanding Myriad company's competitive advantages is key to its future success.

Myriad Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔